[25-NSE] Accelerate Diagnostics, Inc. SEC Filing

Rhea-AI Filing Summary

Nasdaq Stock Market LLC has filed Form 25 to remove Accelerate Diagnostics, Inc. (AXDX) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The notice, signed on 2025-07-21 by Hearings Advisor Aravind Menon, states that Nasdaq believes it meets all requirements for the filing. The company’s securities will cease to be listed once the Form 25 becomes effective and the Exchange Act registration will be withdrawn unless the SEC objects. No financial or earnings data accompany this low-complexity filing; the sole purpose is the formal delisting of AXDX shares.

Positive

• None.

Negative

• Nasdaq has initiated formal delisting of Accelerate Diagnostics common stock via Form 25, ending Section 12(b) registration and likely reducing liquidity and investor protections.

Insights

Equity Analyst

TL;DR: Nasdaq's Form 25 initiates AXDX delisting, eliminating exchange trading and Section 12(b) registration—materially negative for current shareholders.

The filing confirms that Accelerate Diagnostics’ common stock will be stricken from Nasdaq’s listing roster. Delisting typically reduces liquidity, impairs price discovery, and may trigger institutional ownership restrictions. While registration under Section 12(g) may persist, investors should expect trading to migrate to OTC venues with wider spreads and lower volumes. No financial justification or remediation plan is provided, suggesting limited near-term prospects for relisting.

Corporate Governance Specialist

TL;DR: Formal compliance step; absence of issuer opposition indicates acceptance of delisting outcome.

Nasdaq certifies rule compliance under 17 CFR 240.12d2-2(b). The lack of issuer-filed objections implies the company either requested or did not contest removal. Governance risk rises as reduced disclosure requirements may follow once Section 12(b) registration ends. Minority investors lose exchange protections such as timely corporate actions processing.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-31822

Issuer:	Accelerate Diagnostics, Inc
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3950 S. Country Club Road
	Tucson	ARIZONA	85714
Telephone number:					520-365-3100

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-07-21	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Nasdaq file Form 25 for Accelerate Diagnostics (AXDX)?

The filing notifies the SEC of Nasdaq's decision to remove AXDX common stock from exchange listing and Section 12(b) registration.

When was the Form 25 for AXDX signed?

The document was signed on 2025-07-21 by Aravind Menon, Hearings Advisor for Nasdaq.

What class of securities is being delisted?

The filing pertains to common stock of Accelerate Diagnostics, Inc.

What regulatory rule governs this delisting?

Nasdaq cites compliance with 17 CFR 240.12d2-2(b) for striking the security from listing.

Does the filing include financial results or guidance?

No. The Form 25 solely addresses delisting and contains no financial or earnings information.